Movement Disorders: A Clinical and Therapeutic Approach Shyamal Kumar Das
INDEX
A
Abnormal eye movements 104
Acquired basal ganglia disorders 126
acquired hepatocerebral syndrome 126
basal ganglia calcification 127
hypoxic-ischemic encephalopathy 127
magnetic resonance spectroscopy 127
methanol toxicity 127
Wernicke-Korsakoff syndrome 127
Aetiopathogenesis of Parkinson’s disease 176
Alternative therapies 206
acupuncture 211
ayurvedic medicine 206
exercise 212
folic acid and folinic acid 209
manual therapy 214
nutritional supplements 211
physical therapies 208
speech therapy 215
vitamin D and vitamin K2 210
vitamins 209
Amyotrophic lateral sclerosis 126
Approach to movement disorders 17
Approaches to a patient with sleep related movement disorder 145
history 145
investigations 145
physical examination 145
B
Basal ganglia 7
anatomy 7
amygdaloid complex 8
caudate nucleus 7
claustrum 8
lentiform nucleus 8
basal ganglia circuits 13
biochemistry 14
components 7
cross-sectional view 7
physiology 12
Behcet’s disease 44
Bell’s phenomenon 102
Bobble-head doll syndrome 525
Botulinum toxin 467
adverse effects 471
basic pharmacology 468
clinical applications 473
dosage range 475
immunogenicity 470
mechanism of action 469
Bradykinesia 27
C
Cardiac dysrhythmias 245
Cardiovascular dysfunction 242
Caudal vermis syndrome 448
Causes of dystonia 36
Cell divison 54
Cerebellar cortical degeneration 124
Cerebellar degenerative disorder 123
Cerebellar syndromes 448
Cervical dystonia 479
Chorea 25
Chromosomal basis of heredity 53
human chromosome 54
Churg-Strauss syndrome 43
Classification of genetic disorders 53
chromosomal disorder 53
multifactorial disorder 53
single-gene disorder 53
Cogwheel rigidity 27
Cortical control of saccades 95
Cortico-basal-ganglionic degeneration 102, 123, 171
differential diagnosis 173
imaging 172
pathology 173
D
Degenerative cerebellar disease 450
Diffuse Lewy body disease 170
differential diagnosis 171
imaging 171
management 171
pathology 171
Dimentia in Parkinson disease 182
Binswanger encephalopathy 192
clinical features 189
cognitive dysfunction 186
diagnosis 189
differential diagnosis 192
diffuse Lewy body disease 192
investigation 193
neurochemistry 188
neuropathology 188
pathophysiology 187
risk factors 187
treatment 193
Dopa responsive dystonia 279
clinical features 284
differential diagnosis 285
genetic basis 282
pathology 283
prognosis 289
treatment 289
Dopamine agonists 202
Dopamine receptor agonists 489
Dopamine receptor blockers 336
atypical neuroleptics 336
catecholamine β-agonist 337
targeted combined pharmacotherapy 337
typical neuroleptics 336
Drug induced dyskinesia 378
clinical features 379
epidemiology 379
management 385
pathogenesis 380
Dystonia 22, 78, 253
classification 253
clinical features 253
differential diagnosis 255
dystonia-plus syndromes 82
DYT11 85
generalized dystonia 256
genetics 78
mixed dystonias 82
predominantly focal 82
DYT7
predominantly generalized dystonia 80
DYT1 81
DYT2 81
DYT4 81
rapid-onset dystonia parkinsonism 86
secondary dystonia 258
segmental dystonias 256
types 255
x-linked dystonia parkinsonism 87
paroxysmal dyskinesias 88
E
Electrophysiology 459
dystonia 459
myoclonus 460
Epidemiology of movement disorders 33
Extrapontine osmotic myelinolysis 131
Eye movements 94
importance 94
F
Fahn-Marsden scale 299
Familial Parkinson’s disease 177
Friedreich ataxia 451
G
Gait disorders 107
examination 110
falls 118
collapsing falls 118
toppling falls 118
tripping falls 118
history 109
investigation 118
management 118
mechanism 108
neural control 109
physiology 108
syndromic classification 117
slow shuffling gait 117
veering gait 118
Gaze holding 97
Gene mapping 67
Genetic variation in individuals 65
mutations and polymorphisms 65
causes of mutations 67
DNA repair 67
mutation affecting gene-expression 66
nucleotide substitutions 66
somatic and germ-line mutation 67
unstable mutation 66
Genetics of Parkinson’s disease 69
alpha-synuclein 70
DJ-1 73
leucine rich repeat kinase 2 74
lysosomal type 5P-type ATPase 75
Parkin 71
pink 1 72
ubiquitin C-terminal hydrolase 72
Geste-antagonistique 20
Gilles de la Tourette syndrome 103
H
Hallervorden-Spatz disease 125, 312
diagnostic criteria 314
differential diagnosis 314
genetics 312
management 315
neuropathology 312
pathogenesis 313
Hemiballism 418
causes 418
clinical features 420
epidemiology 418
pathophysiology 419
prognosis 422
treatment 420
Hereditary chin tremor 396
Hoehn and Yahr scale 149
Holmes’s tremor 395
Human genome 55
central dogma 58
DNA structure 55
fundamentals of gene expression 57
gene structure 55
genetic code 60
organization 55
post-translational modification 60
transcription 58
translation 58
Human genome project 67
Huntington’s disease 103, 409
assessment 412
clinical presentation 409
diagnosis 412
epidemiology 409
genetics 413
management 415
pathogenesis 414
pathology 414
I
Idiopathic Parkinson’s disease 149
clinical features 151
clinical subgrouping 150
depressive illness 157
diagnosis 154
differential diagnosis 155
Dopa responsive dystonia 156
drug induced parkinsonism 156
investigation 157
biochemical investigation 157
imaging 157
genetic study 157
management 158
early 159
late 159
normal pressure hydrocephalus 157
Parkinsonism plus syndrome 156
post encephalitic parkinsonism 156
surgical management 160
vascular parkinsonism 157
Immunologic chorea 42
Infantile tremor syndrome 326
Involuntary movement disorders 133
K
Keyser-Fleischer ring 21, 266
Kinetic tremor 29
L
Leigh disease 128
Lewy bodies 151
M
Management of motor complications 198
Moersch-Woltmann syndrome 437
Molecular pathogenesis of Parkinson’s disease 75
Movement disorders 3
characteristics 19
clinical features 20
abnormal posturing 20
associated peripheral neuropathy 21
associated pyramidal tract involvement 21
associated sphincter disturbance 22
bradykinesia 20
cognitive dysfunction 21
gait abnormality 20
ocular examination 21
ocular movement disorders 20
rigidity 20
speech abnormality 20
systemic illness 22
tremor 20
physiology 3
Multiple system atrophy 122, 167
differential diagnosis 169
imaging 168
management 169
pathology 168
role of electrophysiology 168
Muscle cramp 433
Myoclonus 23, 400
classification 400
diagnosis 402
management 405
pharmacotherapy 407
N
Neurodegenerative disorder 48
dystonia 49
Parkinson disease 48
Neuroleptic malignant syndrome 381
Neuromyotonia 46
Non-neuroleptic induced dyskinesia 385
Non-schizophrenic disorders 370
O
Obsessive compulsive disorder 38
Occupational dystonias 293
aetiopathogenesis 293
clinical subtypes 295
diagnosis 297
musician’s focal dystonia 296
treatment 297
Ocular flutter and opsoclonus 100
Opsoclonus- myoclonus 46
Optokinetic eye movements 99
Organization of the saccadic system 96
Oromandibular dystonia 480
P
Pancerebellar syndromes 449
Parkinson’s disease 34
Parkinson’s disease and depression 228
characteritics 232
management 233
pathophysiology 232
prevalence 231
Parkinsonism plus syndromes 162
course and prognosis 167
differential diagnosis 164
etiology 166
imaging 164
pathology 164
Paroxysmal dyskinesias 303
diagnosis 309
management 309
pathophysiology 308
Paroxysmal exertion induced dyskinesia 306
Paroxysmal hypnogenic dyskinesia 306
Paroxysmal movement disorders in sleep 27
Paroxysmal non-kinesigenic dyskinesia 305
Patterns of single gene inheritance 63
autosomal dominant inheritance 64
autosomal recessive inheritance 64
mendelian inheritance 64
mode of transmission 63
X-inactivation 65
X-linked inheritance 65
Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection 344
clinical features 345
etiopathogenesis 348
management 350
pathogenesis 347
Pediatric movement disorders 319
investigations 326
prognosis 329
surgical management 328
Pharmacological approach to treatment of movement disorders 487
choreic disorders 496
pathology 496
pharmacotherapy 497
dystonias 491
neurotransmitter abnormalities 491
pharmacotherapy 491
essential tremor 494
pathology 495
pharmacotherapy 495
myoclonus 492
neurotransmitter abnormalities 493
pharmacotherapy 494
Parkinson’s disease 488
pharmacotherapy 489
tic disorders 497
neurotransmitter abnormalities 497
pharmacotherapy 497
Post stroke movement disorders 510
blepharospasm 512
epidemiology 510
hand tremor 516
head tremor 516
hemiakathisia 513
hemiballism and biballism 512
hemibody tremor 516
hemichorea 511
limb shaking TIAs 514
myoclonus 512
post stroke dystonia 513
rubral tremor 516
thalamic tremors 515
tremor 515
vascular Parkinsonism 514
violent tremor 516
Post traumatic movement disorders 519
Postural tremor 28
Progressive supranuclear palsy 102, 122
Psychogenic movement disorders 357
clinical features 359
diagnostic criteria 367
epidemiology 357
management 368
prognosis 368
Q
Quality of life 503
R
Rabbit syndrome 385
Rest tremor 28
Restless leg syndrome 141
Rett syndrome 429
differential diagnosis 431
genetic studies 431
laboratory studies 430
management 432
prognosis 430
reasons 431
Role of brainstem nuclei 97
Role of genetics in medicine 52
Role of levodopa 199
Rostral vermis syndrome 448
S
Saccadic eye movement 94
Schönlein purpura 43
Schwartz-Jampel syndrome 437
Serotonin syndrome 382
Sexual dysfunction 241
Sleep and movement disorders 137
chemistry 138
neurobiology 138
stages of sleep 137
Sleep bruxism 462
Sleep related movement disorders 139
individual disorders 139
clinical features 140
epidemiology 140
etiology 140
pathophysiology 140
REM sleep behavior disorder 139
treatment 140
Smooth pursuit 98
Spasmodic dysphonia 483
Specific disorders related clinical approach 22
Spontaneous eye movements 104
Sporadic Parkinson’s disease 179
inflammatory action 182
mitochondrial dysfunction 181
oxidative stress 180
proteolytic stress 182
Stereotypic movement disorder 426
differential diagnosis 427
epidemiology 427
etiology 427
prognosis 428
treatment 429
Stiff-leg syndrome 46
Stiff-person syndrome 45
Sudomotor dysfunction 246
Surgery for Parkinson’s disease 219
deep brain stimulation 228
direct and indirect pathways 221
procedure of deep brain stimulation 225
globus pallidus interna 226
nucleus of thalamus 226
subthalamic nucleus 225
ventral intermedio-lateral 226
role of dopamine 221
role of surgery in Parkinson’s disease 222
pallidotomy 223
subthalamotomy 224
thalamotomy 223
stimulator hardware 226
target localization 227
Sydenham’s chorea 339
epidemiology 339
etiopathogenesis 339
pathology 340
pathophysiology 340
clinical features 341
diagnosis 342
treatment 343
Sydenham’s chorea 42
T
Tardive 383385
akathisia 385
dyskinesia 383
dystonia 384
myoclonus 385
stereotype 383
tourettism 384
tremor 384
Tics disorders 24, 330
classification 331
clinical characteristics 331
differential diagnosis 334
treatment 335
Tools of human molecular genetics 60
molecular diagnosis 60
application of PCR in molecular diagnosis 62
restriction fragment length polymorphism 61
Southern blot 61
Tourette’s syndrome 42, 332
Tremor 28, 76, 391
differential diagnosis 397
treatment 397
types 393
cerebellar tremor 395
dystonic tremor 395
odd or atypical tremor 395
orthostatic tremor 396
palatal tremor 396
primary writing tremor 396
psychogenic tremor 396
voice tremor 395
U
Urinary dysfunction 240
V
Vergence system 99
Vertical gaze 99
Vestibular system 98
W
Whipple disease 104
Wilson’s disease 38, 103, 124, 261
ceruloplasmin 263
clinical presentations 264
diagnosis 267
differential diagnosis 270
epidemiology 262
hepatic manifestations 266
metallothionein 263
neuroimaging 267
pathogenesis 263
pathology 264
prognosis 277
treatment 273
×
Chapter Notes

Save Clear


1Basic Chapters2

Movement Disorders as a Subspecialty of Neurology and an Introduction to the Physiology of MovementCHAPTER 1

Mark Hallett
‘Movement disorders' is a growing subspecialty of neurology. It is of interest to consider what is responsible for this growth. Taking the broad view, a driving factor is the growth of medical knowledge and the progressive subdividing of medical expertise. Neurology is getting so large that it is difficult to be expert in all of it. This is leading to subspecialization. At present in the United States, this subspecialization is being formally recognized by the American Board of Psychiatry and Neurology and the United Council for Neurologic Subspecialties. Movement disorders began to develop with the interest in Parkinson disease, and in particular, with the development of treatment for Parkinson disease. At the outset movement disorders encompassed only disorders of the basal ganglia, and included, for example, dystonia and Huntington disease as well as Parkinson disease. A group of neurologists, colleagues and students of C. David Marsden and Stanley Fahn, began to talk about movement disorders rather than basal ganglia disorders. Other disorders involving movement were added to the field. Interest was always enhanced by the development of therapies, and, as another example, myoclonus became a more relevant topic after the discovery that it could be ameliorated by 5-hydroxytryptophan. The ataxias were added relatively late since interest in them focused on the cerebellum rather than the basal ganglia. Spasticity joined only very recently after the demonstration that botulinum toxin injections could be helpful.
Local interest groups on movement disorders began to spring up, and these were often called basal ganglia clubs at first (and some still retain that name). One activity that stimulated interest was patient discussions centered around showing videotapes of the patients. Marsden and Fahn initiated a dinner meeting at the American Academy of 4Neurology where they and the participants would bring videotapes of “unusual” movement disorders, and these discussions would go on well passed the designated closing time. On the international level, Fahn and Marsden started a society, the Movement Disorder Society (MODIS), with a journal called Movement Disorders. The journal had the novel feature of including videotapes to illustrate the articles. Reiner Benecke and Marsden had the idea for an international society to have meeting about movement disorders, and they called this the International Medical Society for Motor Disturbances (ISMD). MODIS joined ISMD for the meeting in Washington, DC in 1990 that was called the First International Congress on Movement Disorders. This was successful, and the two societies merged in the next two years to form a “new” society called the Movement Disorder Society (MDS). MDS has grown to be a very successful international society with an important journal and active yearly meetings.
Movement disorders encompass all neurologic disorders characterized by abnormal movements. While most practices are dominated by patients with Parkinson disease, the variety of patients is very broad. The prevalence of different movement disorders is in (Table 1.1).
Research in movement disorders is very active on multiple levels. Areas include the basic physiology of movement, the pathophysiology of disordered movement, genetics, cell biology, pharmacology, and clinical trials. Therapeutics is expanding and includes drugs, surgery, injectables such as botulinum toxin, and rehabilitation methods. Basic research encompasses mechanisms of neuro-degeneration and the potential use of stem cells. The rapid changes in therapeutic options make continuing medical education a necessity and a challenge.
Table 1.1   Prevalence of movement disorders
Disorder
Prevalence per 100,000
Restless legs syndrome
9800
Essential tremor
415
Parkinson disease
187
Tourette syndrome
29 to 2990
Primary torsion dystonia
33
Hemifacial spasm
7.4 to 14.5
Blepharospasm
13.3
Hereditary ataxia
6
Huntington disease
2 to 12
Wilson disease
3
Progressive supranuclear palsy
2 to 6.4
Multiple system atrophy
4.4
Table modified from Fahn S, Jankovic J. Principles and Practice of Movement Disorders. Elsevier, Amsterdam, 2007, in press. See original for references.
Subsequent chapters in this book cover all areas of clinical movement disorders and the approach to the patient in detail. It is valuable at the onset to consider in broad terms how movement is generated (Fahn and Jankovic 2007).
Movement, whether voluntary or involuntary, is produced by the contraction of muscle. Muscle, in turn, is normally controlled entirely by the anterior horn cells or alpha motoneurons. Some involuntary movement disorders arise from muscle, alpha motoneuron axon, or the alpha motoneuron itself. As the sole controller of muscle, the alpha motoneuron is clearly important in understanding the genesis of movement. The influences upon the alpha motoneuron are many and complex, but have been extensively studied. Inputs onto the alpha motoneuron can be divided into the segmental inputs and the supraspinal inputs.
The main supraspinal control comes from the corticospinal tract. Approximately 30% of 5the corticospinal tract arises from the primary motor cortex, and other significant contributions come from premotor cortex and sensory cortex. Other cortical neurons project to basal ganglia, cerebellum and brainstem, and these structures can also originate spinal projections. Particularly important is the reticular formation that originates several reticulospinal tracts with different functions. The rubrospinal tract, originating in the magnocellular division of the red nucleus, while important in lower primates, is virtually absent in humans.
The basal ganglia circuitry and cerebellar circuitry both can be considered as subcortical loops that largely receive information from the cortex and return most of the output back to cortex via the thalamus. Both also have smaller directly descending projections. Although both loops utilize the thalamus, the relay nuclei are separate, and the loops remain largely separate.
The basal ganglia loop anatomy is complex with many connections, but a simplification has become popular that has some value. In this model there are two pathways that go from cortex and back to cortex again. The direct pathway is putamen, internal division of the globus pallidus (GPi), and thalamus (mainly the Vop nucleus). The indirect pathway is putamen, external division of the globus pallidus (GPe), subthalamic nucleus (STN), GPi, and thalamus. The substantia nigra, pars compacta, (SNc) is the source of the important nigro-striatal dopamine pathway and appears to modulate the loop, although not being in the loop itself. The contribution of the basal ganglia to movement remains controversial. One possibility is that they contribute to refining movement by working in a center-surround mechanism.
Basal ganglia disorders are characterized by a wide variety of movement signs and symptoms. Often they are divided into hypokinetic and hyperkinetic varieties, implying too little movement on the one hand and too much movement on the other.
The anatomy of the cerebellar pathways, like the basal ganglia pathways, is complex, but there are simplified models that aid thinking. The main cortico-cerebellar-cortical loop is frontal lobe, pontine nuclei, cerebellar cortex (via middle cerebellar peduncle), deep cerebellar nuclei, red nucleus and VL thalamus (via superior cerebellar peduncle), and motor cortex. The input fibers to the cerebellar cortex are the mossy fibers that synapse onto granule cells which in turn synapse onto the Purkinje cells. There is also extensive sensory input via spinocerebellar tracts, largely carried in the inferior cerebellar peduncle. A critical modulatory loop involves the inferior olivary nucleus. The inferior olive innervates both the cerebellar cortex and deep nuclei via the inferior cerebellar peduncle and the climbing fibers that synapse directly onto Purkinje cells. Feedback returns to the inferior olive by a dentate-olivary pathway that travels in the superior cerebellar peduncle, goes around the red nucleus and descends in the central tegmental tract. The cerebellum clearly involves the fine control of the timing of movement, and patients with cerebellar lesions have ataxia, disorganized, poorly coordinated or clumsy movement.
The primary motor cortex provides the principal output to the corticospinal tract. Thus, its inputs determine the brain's contribution to movement. The main inputs come from the premotor cortices, including the lateral premotor cortex, the supplementary 6motor area, and the caudal parts of the cingulate motor area. These areas in turn receive their input from wide areas of brain including the presupplementary motor area, rostral parts of the cingulate motor area, dorsolateral prefrontal cortex, and parietal areas. There has been considerable attention recently to the parietal-premotor connections, which are highly specific and appear to provide important links between sensory and motor function.
The apraxias are disorders of motor control, characterized by a loss of the motor program, not explicable by more elemental motor, sensory, coordination or language impairments. Idiomotor apraxia is present when there is knowledge of the task, but there are temporal and spatial errors in performance. It has long been suspected to be due to a disconnection between parietal and premotor areas.
There are many disorders where there is some confusion as to whether a movement is voluntary or involuntary. There is only limited understanding of the nature of voluntariness. Examples include tics in Tourette syndrome and psychogenic movement disorders.
As is apparent, movement disorders can arise almost anywhere in the central nervous system. This gives rise to the incredible diversity of symptoms and disorders, and makes differential diagnosis a challenge. This book will be a helpful guide for diagnosis and therapy.
FURTHER READING
  1. Fahn S, Jankovic J. Principles and Practice of Movement Disorders. Elsevier,  Amsterdam,  2007, in press.